Bausch Health Companies Inc (NYSE:BHC) Expected to Announce Quarterly Sales of $1.81 Billion

Equities research analysts expect that Bausch Health Companies Inc (NYSE:BHC) will announce sales of $1.81 billion for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Bausch Health Companies’ earnings, with the lowest sales estimate coming in at $1.74 billion and the highest estimate coming in at $1.89 billion. Bausch Health Companies posted sales of $2.15 billion in the same quarter last year, which suggests a negative year-over-year growth rate of 15.8%. The firm is scheduled to report its next earnings results on Tuesday, August 4th.

According to Zacks, analysts expect that Bausch Health Companies will report full-year sales of $8.06 billion for the current financial year, with estimates ranging from $7.98 billion to $8.13 billion. For the next fiscal year, analysts expect that the firm will post sales of $8.65 billion, with estimates ranging from $8.42 billion to $8.95 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Bausch Health Companies.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.88 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.88. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $2.03 billion. Bausch Health Companies had a negative net margin of 21.96% and a positive return on equity of 84.58%. The business’s revenue was down .2% on a year-over-year basis. During the same period last year, the company earned $1.03 earnings per share.

Several research analysts recently weighed in on BHC shares. ValuEngine upgraded shares of Bausch Health Companies from a “strong sell” rating to a “sell” rating in a report on Thursday, June 25th. SunTrust Banks cut their price target on shares of Bausch Health Companies from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, May 8th. TheStreet cut shares of Bausch Health Companies from a “c-” rating to a “d+” rating in a report on Friday, April 3rd. HC Wainwright boosted their price target on shares of Bausch Health Companies from $50.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Finally, Citigroup started coverage on shares of Bausch Health Companies in a report on Friday, April 24th. They set a “buy” rating and a $30.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Bausch Health Companies has an average rating of “Buy” and a consensus target price of $32.06.

In related news, Director John Paulson purchased 2,041,036 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was acquired at an average price of $17.35 per share, with a total value of $35,411,974.60. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Holdings L.P. Valueact purchased 948,353 shares of the business’s stock in a transaction on Friday, June 5th. The stock was bought at an average cost of $19.24 per share, with a total value of $18,246,311.72. The disclosure for this purchase can be found here. In the last three months, insiders acquired 4,618,309 shares of company stock valued at $79,509,247. Corporate insiders own 12.14% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Envestnet Asset Management Inc. bought a new position in shares of Bausch Health Companies in the 4th quarter worth approximately $1,203,000. Rockefeller Capital Management L.P. bought a new position in shares of Bausch Health Companies in the 1st quarter worth approximately $63,000. Capital World Investors lifted its stake in shares of Bausch Health Companies by 375.5% in the 4th quarter. Capital World Investors now owns 950,922 shares of the company’s stock worth $28,452,000 after purchasing an additional 750,922 shares during the period. The Manufacturers Life Insurance Company raised its stake in Bausch Health Companies by 55.1% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,808,047 shares of the company’s stock worth $27,704,000 after acquiring an additional 642,647 shares during the period. Finally, Credit Suisse AG raised its stake in Bausch Health Companies by 47.0% during the 4th quarter. Credit Suisse AG now owns 785,262 shares of the company’s stock worth $23,495,000 after acquiring an additional 251,201 shares during the period. 68.94% of the stock is owned by institutional investors.

Shares of NYSE BHC traded up $0.10 during mid-day trading on Friday, reaching $18.29. 178,238 shares of the company’s stock traded hands, compared to its average volume of 4,942,722. The stock has a market cap of $6.45 billion, a P/E ratio of -3.39, a PEG ratio of 0.45 and a beta of 1.26. The business has a 50-day simple moving average of $18.28 and a 200 day simple moving average of $22.02. Bausch Health Companies has a 1-year low of $11.15 and a 1-year high of $31.97.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

See Also: What is a management fee?

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.